PPP2R1A

Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2024 Financial Results

Retrieved on: 
火曜日, 5月 7, 2024
Research, FDA, Genetics, Clinical Trials, Biotechnology, Pharmaceutical, Health, Science, Oncology, Other Science, Net, Safety, Food, Irinotecan, CCNE1, PPP2R1A, Lung cancer, BID, ESMO, Adolescence, PLK4, PKMYT1, Data, Bristol Myers Squibb, Patient, WEE1, FBXW7, Biomarker, Clinical trial, Annual general meeting, Therapy, NSCLC, FOLFIRI, G&A, Pharmaceutical industry

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the first quarter ended March 31, 2024.

Key Points: 
  • Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the first quarter ended March 31, 2024.
  • “This was a quarter of clinical progress as we await key, near-term data on a rich set of distinctive clinical approaches for our four wholly-owned compounds in 2024,” said Lloyd M. Segal, President and Chief Executive Officer of Repare.
  • We are seeing continuing trends of patient response and benefit, and we are on track to report the updated dataset in the fourth quarter of 2024.
  • The increase in revenue for the three-month period was primarily due to the $40.0 million Roche milestone achievement in the first quarter of 2024.

Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
水曜日, 2月 28, 2024
Biotechnology, Pharmaceutical, Health, Oncology, CCNE1, Quarter, Adolescence, Research, Arm, PPP2R1A, PARP, FBXW7, Net, FOLFIRI, AACR, Conference, BMS, ADP, PLK4, Clinical trial, Safety, Therapy, Patient, RECIST, Nature Medicine, IND, ATR, WEE1, Partnership, Pharmaceutical industry

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the fourth quarter and full year ended December 31, 2023.
  • Repare will sponsor the global clinical trial as a new arm in the ongoing MYTHIC trial, with costs being shared equally by Debiopharm and Repare.
  • Disclose additional camonsertib clinical development plans beyond the TRESR and ATTACC clinical trials sponsored by Repare in the second quarter of 2024.
  • Fourth Quarter and Full Year 2023 Financial Results:
    Cash, cash equivalents, and marketable securities: Cash, cash equivalents, and marketable securities as of December 31, 2023 were $223.6 million.

Repare Therapeutics Provides Corporate Update and Highlights Anticipated Key 2024 Milestones

Retrieved on: 
月曜日, 1月 8, 2024
Biotechnology, Pharmaceutical, Oncology, Health, Data Management, Technology, Genetics, Clinical Trials, Immunotherapy, CCNE1, Conference, AACR, ATR, Partnership, Debiopharm, Arm, RECIST, Adolescence, FOLFIRI, WEE1, PPP2R1A, Therapy, PARP, RLT, Nature Medicine, Clinical trial, ADP, FBXW7, Patient, Safety, PLK4, Pharmaceutical industry

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today provided a corporate update and highlighted key milestones anticipated in 2024.

Key Points: 
  • Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today provided a corporate update and highlighted key milestones anticipated in 2024.
  • Repare will sponsor the global study as a new arm in the ongoing MYTHIC study with costs being shared equally by Debiopharm and Repare.
  • Initiation of a Phase 1 dose finding study of RP-3467, a potential best-in-class Polθ inhibitor, in the second half of 2024.
  • Repare ended 2023 with approximately $223 million in cash, cash equivalents and marketable securities, which is anticipated to fund planned operations into mid-2026.

Repare Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results

Retrieved on: 
木曜日, 11月 9, 2023
Oncology, Health, Genetics, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Neoplasm, Research, PRS, Carboplatin, Ovarian cancer, Trae Waynes, Traveller Alien Module 2: K'kree, Oncology nursing, Partnership, CBR, September 5, ATR, CCNE1, Circulating tumor DNA, OR, BMS, Paclitaxel, Ono, Clinical Ovarian Cancer & Other Gynecologic Malignancies, Glomus tumor, Roche, Net, Safety, Therapy, Cancer, Patient, DNA, MRR, Conference, Clinical trial, Anemia, IST, AACR, Red Barricades: ASL Historical Module 1, FOLFIRI, Genotype, PPP2R1A, PKMYT1, FBXW7, Princess Margaret Cancer Centre, RECIST, Modularity, PARP, Pharmaceutical industry, Vaccine, Reinsurance, Reparenting, G&A, IND

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the third quarter ended September 30, 2023.

Key Points: 
  • Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the third quarter ended September 30, 2023.
  • In the cohort of patients with gynecologic tumors, the RECIST response was 50%, OR was 60%, and CBR was 70%.
  • These patients also had a median of 3 and up to 9 prior lines of therapy, before administration of lunresertib.
  • RP-3467 is Repare’s wholly-owned Polθ inhibitor, currently in IND-enabling studies, which began in the second quarter of 2023 and remain ongoing.

Repare Therapeutics Announces Positive Initial Data from Phase 1 MYTHIC Clinical Trial Evaluating Lunresertib Alone and in Combination with Camonsertib

Retrieved on: 
金曜日, 10月 13, 2023
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Clinical Trials, September 5, FRCP, Pharmacokinetics, Doctor of Philosophy, Modularity, Drug, Glomus tumor, MBBS, AACR, Anemia, MD, Traveller Alien Module 1: Aslan, Traveller Alien Module 2: K'kree, Safety, NCT, University, MD Anderson Cancer Center, PPP2R1A, Patient, MRR, RECIST, Therapy, CCNE1, ATR, Trae Waynes, PKMYT1, Genotype, Principal investigator, Neoplasm, Roche, FBXW7, Conference, OR, CBR, Gynecologic cancer disparities in the United States, Pharmaceutical industry, Vaccine, Medical imaging, Dietary supplement, Reparenting

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported positive initial data from Modules 1 and 2 of its ongoing Phase 1 MYTHIC clinical trial evaluating lunresertib alone and in combination with camonsertib, an ATR inhibitor.

Key Points: 
  • Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported positive initial data from Modules 1 and 2 of its ongoing Phase 1 MYTHIC clinical trial evaluating lunresertib alone and in combination with camonsertib, an ATR inhibitor.
  • Lunresertib (RP-6306) is a first-in-class precision oncology small molecule PKMYT1 inhibitor that targets CCNE1 amplification, FBXW7 and PPP2R1A alterations in solid tumors.
  • Lunresertib is being evaluated alone and in combination with camonsertib (RP-3500 / RG6526), a potent and selective oral inhibitor of ATR developed by Repare and now partnered with Roche for development excluding the lunresertib + camonsertib combination.
  • “We saw early efficacy signals across multiple tumor types and in each genotype selected, most notably in gynecological tumors where the lunresertib + camonsertib combination provides a potential new treatment option for these patients.

Repare Therapeutics to Present Preliminary Phase 1 MYTHIC Module 1 and 2 Data at 35th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Retrieved on: 
火曜日, 9月 19, 2023
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Clinical Trials, Atri, DNA, DDR, Ataxia, Roche, Clinical trial, Traveller Alien Module 4: Zhodani, MD Anderson Cancer Center, Patient, University, PKMYT1, Memorial Sloan Kettering Cancer Center, CCNE1, FBXW7, Therapy, Conference, ATR, PPP2R1A, Pharmaceutical industry, Dietary supplement, Communications satellite

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced it will present initial data from Module 1 and 2 of its ongoing Phase 1 MYTHIC clinical trial in a plenary session at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, being held October 11-15, 2023 in Boston, MA.

Key Points: 
  • Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced it will present initial data from Module 1 and 2 of its ongoing Phase 1 MYTHIC clinical trial in a plenary session at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, being held October 11-15, 2023 in Boston, MA.
  • In addition to this presentation, the Company will present multiple posters at the conference highlighting preclinical and clinical developments, including data from Module 4 of its Phase 1/2 TRESR clinical trial.
  • Repare entered into a worldwide license and collaboration agreement with Roche for the development and commercialization of camonsertib.
  • ET
    Presenter: Dr. Ezra Rosen, Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY
    Session date and time: Thursday, October 12 | 12:30 p.m. – 4:00 p.m.

Repare Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results

Retrieved on: 
水曜日, 8月 9, 2023
Oncology, Health, FDA, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, Clinical Ovarian Cancer & Other Gynecologic Malignancies, IST, Neoplasm, RECIST, Rash, MRR, Patient, ATR, PPP2R1A, Diarrhea, Clinical trial, Princess Margaret Cancer Centre, ADP, FOLFIRI, Platinum, Toxicity, Carboplatin, Vomiting, Ono, CCNE1, IND, Safety, Net, DNA, AACR, CBR, American Association for Cancer Research, DNA repair, Anemia, FBXW7, Research, Therapy, PARP, ORR, Partnership, Nature Medicine, Progression-free survival, Paclitaxel, Fast Track, Bristol Myers Squibb, Endometrial cancer, BID, PKMYT1, Nausea, BMS, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, FTD, Food, Aplastic anemia, Pharmaceutical industry, Medical imaging, Vaccine, Reinsurance, G&A, Reparenting

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the second quarter ended June 30, 2023.

Key Points: 
  • Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the second quarter ended June 30, 2023.
  • In April 2023, we received a payment of $4 million from Roche for additional revisions to the clinical development plan under the Roche Agreement.
  • The article, entitled “Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results” can be accessed here .
  • Second Quarter 2023 Financial Results:
    Cash and cash equivalents and marketable securities: Cash and cash equivalents and marketable securities as of June 30, 2023 were $280.7 million, which Repare believes will be sufficient to fund its planned operations into 2026.

Repare Therapeutics Reports Proof of Concept for Lunresertib (RP-6306) in Clinic, Initial Monotherapy Data from Phase 1 MYTHIC Clinical Trial and Early Insights from Ongoing Combination Trials

Retrieved on: 
水曜日, 6月 7, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Pharmacodynamics, PPP2R1A, DNA, Cholangiocarcinoma, TP53, IST, Diarrhea, Princess Margaret Cancer Centre, FOLFIRI, STEP2, RECIST, Pharmacokinetics, Paclitaxel, Toxicity, Carboplatin, Doctor of Philosophy, Rash, Vomiting, DNA repair, MD, Patient, BID, Colorectal cancer, Anemia, Medicine, CCNE1, Nausea, Uterine cancer, FBXW7, Therapy, Safety, ATR, Aplastic anemia, Pharmaceutical industry, Vaccine, Dietary supplement, Medical imaging, PKMYT1, Reparenting

“The data demonstrate that lunresertib effectively inhibits PKMYT1 and offers a synthetic lethal combination with CCNE1 amplification or inactivating mutations in FBXW7 and PPP2R1a.

Key Points: 
  • “The data demonstrate that lunresertib effectively inhibits PKMYT1 and offers a synthetic lethal combination with CCNE1 amplification or inactivating mutations in FBXW7 and PPP2R1a.
  • As of the data cutoff date of April 28, 2023, 63 patients were enrolled in lunresertib monotherapy Module 1 of the MYTHIC study, which is ongoing and accruing patients.
  • Early clinical combination insights demonstrated greater anti-tumor activity in patients treated with the combination of lunresertib and camonsertib than lunresertib alone, based on higher molecular response rates and RECIST 1.1 responses.
  • Repare is also currently evaluating lunresertib in combination with gemcitabine in the Phase 1 MAGNETIC study and in combination with FOLFIRI in the Phase 1 MINOTAUR study.

Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results

Retrieved on: 
火曜日, 2月 28, 2023
Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Clinical Trials, PARP, ASEAN, Therapy, SOX, ADP, Fast Track, Ovarian cancer, Insurance, Partnership, IND, FDA, Patient, Carboplatin, ATM, Regulation of tobacco by the U.S. Food and Drug Administration, D&O, ATR, Probability, CMC, FBXW7, Acceleration, FTD, IST, PKMYT1, CCNE1, Food, Neoplasm, PPP2R1A, Net, Pharmaceutical industry, Cryptocurrency, G&A, Reparenting

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the fourth quarter and full year ended December 31, 2022.

Key Points: 
  • Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the fourth quarter and full year ended December 31, 2022.
  • Evaluating RP-6306, a first-in-class, oral PKMYT1 inhibitor as a monotherapy and in combinations in multiple early clinical studies.
  • Also in January 2023, Repare and Ono amended the Ono Agreement to further extend the research term until July 31, 2023.
  • Fourth Quarter and Full Year 2022 Financial Results:
    Cash and cash equivalents and marketable securities: Cash and cash equivalents and marketable securities as of December 31, 2022 were $343.9 million, which Repare believes will be sufficient to fund its planned operations into 2026.

Inactivating Mutations in Scaffold Component of PP2A, the Target Enzyme of LIXTE Biotechnology’s Clinical Compound LB-100, are Associated with Exceptionally Long Survival of Patients with Ovarian Clear Cell Cancer Treated with Immunotherapy

Retrieved on: 
火曜日, 3月 22, 2022
Company, Cancer, Cell, Survivor, University, MD Anderson Cancer Center, Marketing, Immunotherapy, Society, Clinical trial, OCCC, Reproductive medicine, PP2A, James Hinchcliffe, Survival, Research, Neoplasm, Ovarian cancer, MD, Securities Exchange Act of 1934, Securities Act of 1933, Primary peritoneal carcinoma, CA, U.S. Securities and Exchange Commission, GLOBE, Society of Gynecologic Oncology, Gynecologic Oncology (journal), CTLA4, SGO, Drug Quality and Security Act, Terminology, Patient, Disease, Toxicity, Vaccine, Pharmaceutical industry, PPP2R1A

PASADENA, CA, March 22, 2022 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), notes findings by a team of physician-scientists led by principal investigator Dr. Amir Jazaeri, professor of Gynecologic Oncology and Reproductive Medicine at The University of Texas MD Anderson Cancer Center, and reported at the annual meeting of Society of Gynecologic Oncology (SGO) in Phoenix, AZ, that a subset of patients with ovarian clear cell carcinoma (OCCC) treated with immune checkpoint inhibitors lived significantly longer (had increased overall survival) than most patients with the same disease treated with the same regimens.

Key Points: 
  • Outside research reports that immune checkpoint therapy of patients with ovarian clear cell carcinomas with mutations reducing PP2A activity in their cancers (loss-of-function mutations) correlates with marked clinical benefit.
  • Median overall survival was not reached in seven patients with hotspot inactivation mutations in PPP2R1A versus 6.4 months in the 21 patients without such mutations (p=0.018; HR=0.13 (95% CI: 0.02-0.95).
  • Of note in several patients, response or prolonged disease stabilization leading to longer survival occurred after initial progression.
  • This discussion should be read in conjunction with the Company's filings with the United States Securities and Exchange Commission at www.sec.gov/edgar.shtml